Navigation Links
NexBio Presents Data at ACAAI 2010 Demonstrating Mechanism of Action for Improvement in Airway Function by DAS181 (Fludase®*)
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona.  The presentation was entitled "DAS181 (Fludase®), a Sialidase, Decreases Airway Resistance by Modulating Muscarinic Receptor Signaling."

DAS181 (Fludase®) is an investigational broad spectrum host-targeting antiviral drug candidate undergoing clinical development for the treatment and prevention of Influenza-Like Illness caused by all strains of influenza and parainfluenza (PIV).  These new data show that, independent of its antiviral activity, and by a different mechanism of action, DAS181 may have benefit for airway diseases such as asthma and COPD.

NexBio presented nonclinical data at ACAAI 2009 from studies in three animal models of asthma, demonstrating that DAS181 inhibits airway hyperreactivity characteristic of asthma, as well as airway inflammatory cells and airway mucus, characteristic of chronic airway inflammatory conditions such as COPD.  The current presentation at 2010 ACAAI builds on this prior work by elucidating a key mechanism of action.  The data demonstrate that desialylation of airway muscarinic receptors in both in vivo and in vitro models unexpectedly reduces muscarinic pathway signaling. DAS181 given to mice once daily for three days, at doses lower than those used for antiviral treatment, leads to significantly reduced airway resistance in response to challenge by methacholine.

"The data suggest that DAS181 may have a dual benefit for patients with airway disease who become infected with the respiratory viruses influenza and parainfluenza, as DAS181 may fight infection while simultaneously controlling the underlying airway disease.  These patients are at high risk for exacerbations of their airway disease, as was seen during the 2009 Pandemic, and it is possible that DAS181 may l
'/>"/>

SOURCE NexBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
2. NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009
3. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
4. AAOS Clinical Guideline for Treating Spinal Compression Fractures Presents More Questions Than Answers for Medical Community
5. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
8. Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine
9. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
10. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
11. Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)...  BiOptix is pleased to announce the appointment of Dr. ... and Biochemistry. Scott joins the company after previous scientific leadership ... the course of his nearly 20 year career in ... nationally recognized thought leader in the biosensor field and ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... to Eye via,Ophthalmic Artery, WASHINGTON, March 17 ... retinoblastoma -- a,deadly, inherited cancer of one or ... from having their eyes surgically removed (enucleated),according to ... the Society of,Interventional Radiology,s 33rd Annual Scientific Meeting. ...
... investigational regimen demonstrates important role of, radioimmunotherapy in ... ... remissions, SEATTLE, March 17 Cell Therapeutics, ... that patients with previously,untreated follicular non-Hodgkin,s lymphoma (NHL) ...
Cached Medicine Technology:New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 2New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 3New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 4Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 2Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 3Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 4
(Date:1/22/2015)... 2015 The U.S. Pharmacopeial Convention is ... of Clinical Pharmacy Services at North Carolina State’s College ... the 2015 Beal Award for Distinguished Volunteer Service—the organization’s ... on the contributions of volunteer experts to direct its ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Osteotech, Inc.,(Nasdaq: OSTE ), a global ... musculoskeletal system, announced today that Sam Owusu-Akyaw,Osteotech,s President ... Albany Capital,s Regenerative Technologies Conference in New York.,Mr. ... Eastern Time on,Tuesday, September 11, 2007. Osteotech, ...
... undergone previous heart surgery, Belgian study finds , , MONDAY, Sept. ... tiny openings significantly reduces the risk of death for people ... "We were astonished that the reduction in risk was much ... staff surgeon at the OLV Clinic in Aalst and lead ...
... Sponsorship will provide support for ADA,s Por Tu Familia ... Association (ADA) today announced that Goya Foods, Inc. has ... outreach program, Por Tu,Familia. Por Tu Familia (or "for ... about the seriousness of diabetes,and the importance of a ...
... NEW YORK, Sept. 10 portionpals(R), the fastest ... reached the quarter million,sales mark with no national ... operation. "Our sales are coming strictly from word-of-mouth," ... September 9th, Jamie Moose,of Manistique, Michigan became our ...
... choices , MONDAY, Sept. 10 (HealthDay News) -- U.S. and ... a comprehensive recommendation on how much of what types of ... diets. , Both the American Dietetic Association and the Dietitians ... that 20 percent to 30 percent of energy needs should ...
... Broad Street, LANSDOWNE, Va., Sept. 10 ... by former Philadelphia,Eagle and now pastor Herbert Lusk, ... Christ to bring the women of Philadelphia much ... targeting an,area of downtown Philadelphia, where there are ...
Cached Medicine News:Health News:Small Incisions Make Heart Valve Surgery Safer 2Health News:Small Incisions Make Heart Valve Surgery Safer 3Health News:American Diabetes Association and Goya Foods Inc. Team Up To Support Diabetes Awareness and Outreach in the Latino Community 2Health News:American Diabetes Association and Goya Foods Inc. Team Up To Support Diabetes Awareness and Outreach in the Latino Community 3Health News:Experts Sort Out Good Fats From Bad 2Health News:Women of Philadelphia Win by a 'Touchdown' 2
... an extremely accurate digital A-scan system. The ... probe and fast precise algorithm enables scan ... along the visual axis. The A5500 A-scan ... monitor, built-in thermal printer, 5 different examination ...
... most advanced IOL workstation. Accurate, efficient and ... be used with a variety of regressive, ... to the needs of the patient. Convenient ... a foot pedal for hands-free operation, audible ...
... A-Scan unit with graphic display and IOL ... combination units include firmware module with SRK ... formulas. All model DGH 5000e and DGH ... software reducing the possibility of short readings. ...
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w...
Medicine Products: